Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells

被引:6
|
作者
Yu, Xiao-Hong [1 ]
Xue, Xiaodong [1 ]
Zhu, Xun [2 ]
Li, Xia [1 ]
机构
[1] 903 Hosp, Dept Breast Surg, 113 Middle Posit Taiping Rd, Jiangyou 421700, Sichuan, Peoples R China
[2] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, 1055 Sanxiang Rd, Suzhou 215006, Jiangsu, Peoples R China
关键词
triple-negative breast cancer; receptor interacting protein 140; proliferation; prognosis; RECEPTOR COREPRESSOR RIP140;
D O I
10.3892/ol.2018.8434
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to investigate the expression of receptor interacting protein 140 (RIP140) in triple-negative breast cancer (TNBC), and its association with the prognosis of patients with TNBC. A total of 179 patients with breast cancer were included in this study, with 41 cases of TNBC and 138 cases of non-TNBC. Immunohistochemical staining and western blotting were used to detect the protein expression of RIP140 in the cancerous and paracancerous tissues, revealing that expression of RIP140 was increased in TNBC tissues compared with non-TNBC tissues. High expression of RIP140 in breast cancer tissue was associated with a poorer survival time than low RIP140 expression. Using lentiviral transfection to downregulate RIP140 expression in MDA-MB-231 cells, the effects of RIP140 on the growth and proliferation of breast cancer cells was analyzed using subcutaneous tumors in BALB/c nude mice. Immunohistochemical staining using a Ki-67 antibody in subcutaneous tumor tissue was used to assess the proliferation of MDA-MB-231 cells. The short hairpin RNA-mediated downregulation of RIP140 in MDA-MB-231 cells suppressed the growth and the proliferation of subcutaneous tumors in BALB/c nude mice. Downregulation of RIP140 in breast cancer cells may therefore inhibit the growth and the proliferation of these cells, and may provide a therapeutic target for TNBC.
引用
收藏
页码:8784 / 8788
页数:5
相关论文
共 50 条
  • [41] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [42] MicroRNAs in triple-negative breast cancer
    Koleckova, M.
    Janikova, M.
    Kolar, Z.
    NEOPLASMA, 2018, 65 (01) : 1 - 13
  • [43] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01) : 59 - 66
  • [44] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [45] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [46] MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression
    Yang, Zhi-Xue
    Zhang, Bo
    Wei, Jinrong
    Jiang, Guo-Qin
    Wu, Yan-Lin
    Leng, Bing-Jing
    Xing, Chun-Gen
    CANCER CELL INTERNATIONAL, 2018, 18
  • [47] The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
    He, Lin
    Wick, Neda
    Germans, Sharon Koorse
    Peng, Yan
    CANCERS, 2021, 13 (24)
  • [48] ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
    Zhang, Yang
    Wang, Lu
    Gao, Peng
    Sun, Zhiguo
    Li, Ning
    Lu, Yanqin
    Shen, Jianglun
    Sun, Jian
    Yang, Yiming
    Dai, Hao
    Cai, Haifeng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (05) : 2343 - 2352
  • [49] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [50] COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
    Naoise C. Synnott
    David O’Connell
    John Crown
    Michael J. Duffy
    Breast Cancer Research and Treatment, 2020, 179 : 47 - 56